(Q37291346)

19 August 2017

1 reference

title

Emergence and management of drug-resistant enterococcal infections (English)

1 reference

19 August 2017

Cesar A Arias

1

1 reference

19 August 2017

Barbara E Murray

series ordinal

2

1 reference

19 August 2017

publication date

1 October 2008

1 reference

Expert Review of Anti-infective Therapy

19 August 2017

published in

1 reference

19 August 2017

volume

6

1 reference

19 August 2017

issue

5

1 reference

19 August 2017

page(s)

637-655

1 reference

Vancomycin-resistant enterococcal infections

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Heat resistance of nosocomial enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Emergence of CC17 Enterococcus faecium: from commensal to hospital-adapted pathogen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Prior environmental contamination increases the risk of acquisition of vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Risk of vancomycin-resistant Enterococcus (VRE) bloodstream infection among patients colonized with VRE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Optimizing therapy for vancomycin-resistant enterococci (VRE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Effect of parenteral antibiotic administration on the establishment of colonization with vancomycin-resistant Enterococcus faecium in the mouse gastrointestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Effect of antibiotic therapy on the density of vancomycin-resistant enterococci in the stool of colonized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Optimal therapy for enterococcal endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Deaf or dead? A case of subacute bacterial endocarditis treated with penicillin and neomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Emerging multiply resistant enterococci among clinical isolates. II. Validation of the etest to recognize glycopeptide-resistant strains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Outbreak of Enterococcus gallinarum infections after total knee arthroplasty

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Outcomes Associated With Vancomycin-Resistant Enterococci: A Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Enterococcus faecium bacteremia: does vancomycin resistance make a difference?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Defective killing of enterococci: a common property of antimicrobial agents acting on the cell wall

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Modification of penicillin-binding proteins of penicillin-resistant mutants of different species of enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Novel mechanism of beta-lactam resistance due to bypass of DD-transpeptidation in Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

In vitro studies of plasmid-mediated penicillinase from Streptococcus faecalis suggest a staphylococcal origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Resistance to Six Aminoglycosidic Aminocyclitol Antibiotics Among Enterococci: Prevalence, Evolution, and Relationship to Synergism with Penicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Aminoglycoside resistance in enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

High-level resistance to gentamicin in clinical isolates of enterococci.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Bactericidal activities of antibiotics against vancomycin-resistant Enterococcus faecium blood isolates and synergistic activities of combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

A novel mechanism of resistance to penicillin-gentamicin synergism in Streptococcus faecalis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Aminoglycoside-inactivating enzymes in clinical isolates of Streptococcus faecalis. An explanation for resistance to antibiotic synergism

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Efficacy of ampicillin plus arbekacin in experimental rabbit endocarditis caused by an Enterococcus faecalis strain with high-level gentamicin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Efficacy of the combination ampicillin plus ceftriaxone in the treatment of a case of enterococcal endocarditis due to Enterococcus faecalis highly resistant to gentamicin: efficacy of the "ex vivo" synergism method

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Molecular characterization of Enterococcus faecalis N06-0364 with low-level vancomycin resistance harboring a novel D-Ala-D-Ser gene cluster, vanL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Genetics and mechanisms of glycopeptide resistance in enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

vanC cluster of vancomycin-resistant Enterococcus gallinarum BM4174.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

The vanG glycopeptide resistance operon from Enterococcus faecalis revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Genetic analysis of a high-level vancomycin-resistant isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Failure of daptomycin monotherapy for endocarditis caused by an Enterococcus faecium strain with vancomycin-resistant and vancomycin-susceptible subpopulations and evidence of in vivo loss of the vanA gene cluster

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Mechanism of action of oritavancin and related glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Structure, biochemistry and mechanism of action of glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

The structure of an asymmetric dimer relevant to the mode of action of the glycopeptide antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Toward an estimation of binding constants in aqueous solution: studies of associations of vancomycin group antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Hexapeptide derivatives of glycopeptide antibiotics: tools for mechanism of action studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Pharmacokinetics of oritavancin in plasma and skin blister fluid following administration of a 200-milligram dose for 3 days or a single 800-milligram dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Antimicrobial activity of dalbavancin tested against Gram-positive clinical isolates from Latin American medical centres

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Development of daptomycin for gram-positive infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Endocarditis due to vancomycin-resistant enterococci: case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Serum bactericidal activities of high-dose daptomycin with and without coadministration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

In vivo activity of the combination of daptomycin and fosfomycin compared with daptomycin alone against a strain of Enterococcus faecalis with high-level gentamicin resistance in the rat endocarditis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Daptomycin resistance in Enterococcus faecalis prosthetic valve endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Development of daptomycin resistance in a bone marrow transplant patient with vancomycin-resistant Enterococcus durans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Infective endocarditis caused by daptomycin-resistant Enterococcus faecalis: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

De novo daptomycin nonsusceptibility in a clinical isolate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Mechanisms of resistance to daptomycin in Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Mechanism of action of the oxazolidinone antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Enterococcus faecalis resistant to linezolid: case series and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary care medical center

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Linezolid-resistant, vancomycin-resistant Enterococcus faecium infection in patients without prior exposure to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Linezolid resistance in a clinical isolate of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Recombination Proficiency Influences Frequency and Locus of Mutational Resistance to Linezolid in Enterococcus faecalis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Dose dependence of emergence of resistance to linezolid in Enterococcus faecalis in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

The Cfr rRNA methyltransferase confers resistance to Phenicols, Lincosamides, Oxazolidinones, Pleuromutilins, and Streptogramin A antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Clinical and microbiological aspects of linezolid resistance mediated by the cfr gene encoding a 23S rRNA methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Identification of a plasmid-borne chloramphenicol-florfenicol resistance gene in Staphylococcus sciuri

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

A new mechanism for chloramphenicol, florfenicol and clindamycin resistance: methylation of 23S ribosomal RNA at A2503.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Linezolid for the treatment of multidrug-resistant, gram-positive infections: experience from a compassionate-use program

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Vancomycin-resistant Enterococcus faecalis endocarditis: linezolid failure and strain characterization of virulence factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Treatment of prosthetic valve infective endocarditis due to multi-resistant Gram-positive bacteria with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Isolated pulmonic valve infective endocarditis: a persistent challenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Failure of linezolid treatment for enterococcal endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Successful treatment of vancomycin-resistant Enterococcus faecium endocarditis with linezolid in a renal transplant recipient with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Vancomycin-resistant Enterococcus faecium endocarditis in a premature infant successfully treated with linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Tigecycline: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Overview of tigecycline and its role in the era of antibiotic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Tetracycline antibiotics: mode of action, applications, molecular biology, and epidemiology of bacterial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Ribosomal protection proteins and their mechanism of tetracycline resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

16S rRNA mutation-mediated tetracycline resistance in Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Effects of efflux transporter genes on susceptibility of Escherichia coli to tigecycline (GAR-936).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

AdeIJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in Acinetobacter baumannii

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Tigecycline is modified by the flavin-dependent monooxygenase TetX.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Antibiotic efflux pumps in Gram-negative bacteria: the inhibitor response strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Tigecycline-resistant Enterococcus faecalis strain isolated from a German intensive care unit patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Activity and diffusion of tigecycline (GAR-936) in experimental enterococcal endocarditis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Activity of tigecycline (GAR-936), a novel glycylcycline, against Enterococci in the mouse peritonitis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Rapid development of Acinetobacter baumannii resistance to tigecycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Quinupristin-dalfopristin resistance in gram-positive bacteria: mechanism of resistance and epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Alterations at the peptidyl transferase centre of the ribosome induced by the synergistic action of the streptogramins dalfopristin and quinupristin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

The streptogramin antibiotics: update on their mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

An Enterococcus faecalis ABC homologue (Lsa) is required for the resistance of this species to clindamycin and quinupristin-dalfopristin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Nonsense mutations in the lsa-like gene in Enterococcus faecalis isolates susceptible to lincosamides and Streptogramins A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Identification of vat(E-3), a novel gene encoding resistance to quinupristin-dalfopristin in a strain of Enterococcus faecium from a hospital patient in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Differences in the Enterococcus faecalis lsa locus that influence susceptibility to quinupristin-dalfopristin and clindamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Treatment of vancomycin-resistant Enterococcus faecium infections with quinupristin/dalfopristin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: a synergistic drug combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Endocarditis due to Vancomycin-resistant Enterococcus faecium in an Immunocompromised Patient: Cure by Administering Combination Therapy with Quinupristin/Dalfopristin and High-dose Ampicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Dihydrofolate reductase inhibitors as antibacterial agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Chloramphenicol treatment for vancomycin-resistant Enterococcus faecium bacteremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Prosthetic valve endocarditis due to vancomycin-resistant Enterococcus faecium: treatment with chloramphenicol plus minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

An old antibiotic for a new multiple-resistant Enterococcus faecium?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Successful treatment with ampicillin and fluoroquinolones of human endocarditis due to high-level gentamicin-resistant enterococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Chronic bacterial prostatitis and relapsing Enterococcus faecalis bacteraemia successfully treated with moxifloxacin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Short-course nitrofurantoin for the treatment of acute uncomplicated cystitis in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Recent advances in the formation of the bacterial peptidoglycan monomer unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

In vitro susceptibility of vancomycin-resistant enterococci (VRE) to fosfomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium: potential utility of fosfomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Molecular characterization of a widespread, pathogenic, and antibiotic resistance-receptive Enterococcus faecalis lineage and dissemination of its putative pathogenicity island

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Variant esp gene as a marker of a distinct genetic lineage of vancomycin-resistant Enterococcus faecium spreading in hospitals

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

Glycopeptide Antibiotic Activity and the Possible Role of Dimerization: A Model for Biological Signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.6.5.637

21 January 2018

Identifiers

DOI

10.1586/14787210.6.5.637

1 reference

19 August 2017

1 reference